


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (1):



formula (1)

wherein:

Z is selected from  $-\text{CONR}^{15}\text{OH}$  and  $-\text{N}(\text{OH})\text{CHO}$ ;

$\text{R}^{15}$  is hydrogen or  $\text{C}_{1-3}$ alkyl;

$\text{R}^1$  is hydrogen or a group selected from  $\text{C}_{1-6}$ alkyl,  $\text{C}_{2-6}$ alkenyl,  $\text{C}_{2-6}$ alkynyl,  $\text{C}_{3-7}$ cycloalkyl,  $\text{C}_{5-7}$ cycloalkenyl, aryl and heteroaryl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{2-4}$ alkenyl,  $\text{C}_{2-4}$ alkynyl,  $\text{C}_{3-6}$ cycloalkyl (optionally substituted by one or more  $\text{R}^{17}$ ), aryl (optionally substituted by one or more  $\text{R}^{17}$ ), heteroaryl (optionally substituted by one or more  $\text{R}^{17}$ ), heterocyclyl,  $\text{C}_{1-4}$ alkoxycarbonyl,  $-\text{OR}^5$ ,  $-\text{SR}^2$ ,  $-\text{SOR}^2$ ,  $-\text{SO}_2\text{R}^2$ ,  $-\text{COR}^2$ ,  $-\text{CO}_2\text{R}^5$ ,  $-\text{CONR}^5\text{R}^6$ ,  $-\text{NR}^{16}\text{COR}^5$ ,  $-\text{SO}_2\text{NR}^5\text{R}^6$  and  $-\text{NR}^{16}\text{SO}_2\text{R}^2$ ;

$\text{R}^{16}$  is hydrogen or  $\text{C}_{1-3}$ alkyl;

$\text{R}^{17}$  is selected from halo,  $\text{C}_{1-6}$ alkyl,  $\text{C}_{3-6}$ cycloalkyl and  $\text{C}_{1-6}$ alkoxy;

R<sup>2</sup> is group selected from C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>5-7</sub>cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl where the group is optionally substituted by one or more halo;

R<sup>5</sup> is hydrogen or a group selected from C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>5-7</sub>cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl where the group is optionally substituted by one or more halo;

R<sup>6</sup> is hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

R<sup>8</sup> is hydrogen or a group selected from C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl and C<sub>5-7</sub>cycloalkenyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy and C<sub>1-4</sub>alkyl;

R<sup>3</sup> and R<sup>4</sup> are both hydrogen;

n is 0 or 1;

m is 0 or 1;

D is hydrogen, C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl or fluoro;

X is O, S, SO or SO<sub>2</sub>;

B is monocyclic aryl or heteroaryl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C<sub>1-4</sub>alkyl (optionally substituted by R<sup>13</sup>), C<sub>2-4</sub>alkenyl (optionally substituted by R<sup>13</sup>), C<sub>2-4</sub>alkynyl (optionally substituted by R<sup>13</sup>), C<sub>3-6</sub>cycloalkyl (optionally substituted by R<sup>13</sup>), C<sub>3-6</sub>cycloalkenyl (optionally substituted by R<sup>13</sup>), phenyl (optionally substituted by halo or C<sub>1-4</sub>alkyl), heteroaryl (optionally substituted by halo or C<sub>1-4</sub>alkyl), heterocyclyl (optionally substituted by halo or C<sub>1-4</sub>alkyl), C<sub>1-4</sub>alkylthio, C<sub>3-6</sub>cycloalkylthio, -SOR<sup>13</sup>, -SO<sub>2</sub>R<sup>13</sup>, -SO<sub>2</sub>NHR<sup>13</sup>, -SO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>, -NH<sub>2</sub>SO<sub>2</sub>R<sup>13</sup>, -NR<sup>13</sup>SO<sub>2</sub>R<sup>14</sup>, -NHCONHR<sup>13</sup>, -NHCONHR<sup>13</sup>R<sup>14</sup>, -OR<sup>13</sup>, cyano, -CONR<sup>13</sup>R<sup>14</sup>, -NHCOR<sup>13</sup>, -CO<sup>2</sup>R<sup>13</sup> and -CH<sub>2</sub>CO<sub>2</sub>R<sup>13</sup>;

or B is bicyclic aryl or heteroaryl where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C<sub>1-4</sub>alkyl (optionally substituted by R<sup>13</sup>), C<sub>2-4</sub>alkenyl (optionally substituted by R<sup>13</sup>), C<sub>2-4</sub>alkynyl (optionally substituted by R<sup>13</sup>), C<sub>3-6</sub>cycloalkyl (optionally substituted by R<sup>13</sup>), C<sub>3-6</sub>cycloalkenyl (optionally substituted by R<sup>13</sup>), C<sub>1-4</sub>alkylthio, C<sub>3-6</sub>cycloalkylthio, -SOR<sup>13</sup>, -SO<sub>2</sub>R<sup>13</sup>, -SO<sub>2</sub>NHR<sup>13</sup>, -SO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>, -NHSO<sub>2</sub>R<sup>13</sup>, -NR<sup>13</sup>SO<sub>2</sub>R<sup>14</sup>, -NHCONHR<sup>13</sup>, -NHCONHR<sup>13</sup>R<sup>14</sup>, -OR<sup>13</sup>, cyano, -CONR<sup>13</sup>R<sup>14</sup> and -NHCOR<sup>13</sup>;

R<sup>13</sup> and R<sup>14</sup> are independently hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

or R<sup>13</sup> and R<sup>14</sup> together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkyl, nitro, aryl, heteroaryl, heterocyclyl, *N*-(C<sub>1-4</sub>alkyl)carbamoyl and *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl; or B is naphthyl, quinolinyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl each being optionally substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkyl, aryl, heteroaryl, heterocyclyl and nitro.

3. (Currently amended) A compound according to claim 1 ~~or 2~~ wherein R<sup>1</sup> is a group selected from C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, aryl, heteroaryl and C<sub>1-6</sub>alkyl substituted by aryl or heteroaryl wherein any R<sup>1</sup> group is optionally substituted by one or more substituents independently selected from halo, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkyl and C<sub>3-6</sub>cycloalkyl.

4. (Currently amended) A compound according to ~~any one of claims 1 to 3~~ claim 1 wherein X is O.

5. (Cancelled)

6. (Currently amended) A method, the method comprising treating a disease condition mediated by one or more metalloproteinase enzymes by administering to a warm-blooded animal  
~~The use of a compound according to any one of claims 1 to 4 claim 1 in the manufacture of a medicament in the treatment of a disease condition mediated by one or more metalloproteinase enzymes.~~


7. (Currently amended) A method, the method comprising treating a disease condition mediated by TNF $\alpha$ , by administering to a warm-blooded animal  
~~The use of a compound according to any one of claims 1 to 4 claim 1 in the manufacture of a medicament in the treatment of a disease condition mediated TNF $\alpha$ .~~

8. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 4~~ claim 1; and a pharmaceutically-acceptable diluent or carrier.

9. (Original) A method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound according to claim 1.


10. (Original) A process for preparing a compound of formula (1) according to claim 1 comprising, when Z is -N(OH)CHO, the step of:

a) converting a hydroxylamine of formula (2) into a compound of formula (1);



or when Z is  $-\text{CONR}^{15}\text{OH}$ , the step of:

b) converting an acid of formula (14) into a compound of formula (1);



and thereafter if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.